- Home
- SAFE vs IRWD Comparison
SAFE vs IRWD Comparison
Compare SAFE & IRWD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SAFE | IRWD |
|---|---|---|
| Founded | 2016 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 842.7M | 687.4M |
| IPO Year | 1999 | 2009 |
Fundamental Metrics
Financial Performance| Metric | SAFE | IRWD |
|---|---|---|
| Price | $11.97 | $3.59 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 11 | 4 |
| Target Price | ★ $17.60 | $6.10 |
| AVG Volume (30 Days) | 621.7K | ★ 2.0M |
| Earning Date | 11-04-2026 | 11-09-2026 |
| Dividend Yield | ★ 5.87% | N/A |
| EPS Growth | 7.43 | ★ 1400.00 |
| EPS | ★ 0.82 | 0.55 |
| Revenue | ★ $385,552,000.00 | $298,276,000.00 |
| Revenue This Year | $12.09 | $59.19 |
| Revenue Next Year | $4.69 | $4.80 |
| P/E Ratio | $14.71 | ★ $6.89 |
| Revenue Growth | 5.43 | ★ 8.88 |
| 52 Week Low | $11.60 | $1.43 |
| 52 Week High | $17.45 | $5.78 |
Technical Indicators
Market Signals| Indicator | SAFE | IRWD |
|---|---|---|
| Relative Strength Index (RSI) | 29.47 | 35.47 |
| Support Level | $11.60 | $3.04 |
| Resistance Level | $16.43 | $3.96 |
| Average True Range (ATR) | 0.30 | 0.17 |
| MACD | 0.08 | -0.03 |
| Stochastic Oscillator | 33.07 | 2.78 |
Price Performance
Historical ComparisonAbout SAFE Safehold Inc. New
Safehold Inc is a REIT that operates its business by acquiring, managing, and capitalizing ground leases. Ground leases are long-term contracts between the landlord (the Company) and a tenant or leaseholder. Ground leases generally represent ownership of the land underlying commercial real estate projects that are net leased by the fee owner of the land to the owners/operators of the real estate projects built thereon.
About IRWD Ironwood Pharmaceuticals Inc.
Ironwood Pharmaceuticals Inc is a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal, or GI, and rare diseases. It is focused on the development and commercialization of inventive product opportunities in areas of unmet need, leveraging its demonstrated expertise and capabilities in GI and rare diseases. LINZESS is its commercial product. LINZESS is also available for the treatment of adults with IBS-C or CIC in Mexico, adults with IBS-C or chronic constipation in Japan, and adults with IBS-C in China. Linaclotide is available under the trademarked name CONSTELLA for the treatment of adults with IBS-C or CIC and pediatric patients ages 6-17 years old with FC in Canada, and to adults with IBS-C in certain European countries.